NO2023016I1 - nirsevimab - Google Patents

nirsevimab

Info

Publication number
NO2023016I1
NO2023016I1 NO2023016C NO2023016C NO2023016I1 NO 2023016 I1 NO2023016 I1 NO 2023016I1 NO 2023016 C NO2023016 C NO 2023016C NO 2023016 C NO2023016 C NO 2023016C NO 2023016 I1 NO2023016 I1 NO 2023016I1
Authority
NO
Norway
Prior art keywords
nirsevimab
Prior art date
Application number
NO2023016C
Other languages
English (en)
Norwegian (no)
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of NO2023016I1 publication Critical patent/NO2023016I1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027Paramyxoviridae, e.g. respiratory syncytial virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO2023016C 2014-01-15 2023-04-25 nirsevimab NO2023016I1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461927819P 2014-01-15 2014-01-15

Publications (1)

Publication Number Publication Date
NO2023016I1 true NO2023016I1 (no) 2023-04-25

Family

ID=53543612

Family Applications (1)

Application Number Title Priority Date Filing Date
NO2023016C NO2023016I1 (no) 2014-01-15 2023-04-25 nirsevimab

Country Status (26)

Country Link
US (6) US20160340414A1 (enExample)
EP (3) EP4353316A3 (enExample)
JP (4) JP6836398B2 (enExample)
KR (1) KR102188437B1 (enExample)
CN (2) CN105916520A (enExample)
AU (4) AU2015206570A1 (enExample)
CA (1) CA2933200C (enExample)
CY (2) CY1123425T1 (enExample)
DK (1) DK3094353T3 (enExample)
ES (1) ES2795727T3 (enExample)
FI (1) FIC20230016I1 (enExample)
FR (1) FR23C1016I1 (enExample)
HR (1) HRP20200607T1 (enExample)
HU (2) HUE048855T2 (enExample)
LT (2) LT3094353T (enExample)
LU (1) LUC00305I2 (enExample)
MX (1) MX374517B (enExample)
NL (1) NL301228I2 (enExample)
NO (1) NO2023016I1 (enExample)
PL (1) PL3094353T3 (enExample)
PT (1) PT3094353T (enExample)
RS (1) RS60387B1 (enExample)
SI (1) SI3094353T1 (enExample)
SM (1) SMT202000282T1 (enExample)
TW (1) TWI705974B (enExample)
WO (1) WO2015108967A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
SI3094353T1 (sl) 2014-01-15 2020-07-31 Medimmune, Llc RSY-specifična protitelesa in njihovi funkcionalni deli
US11479600B2 (en) 2016-10-21 2022-10-25 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
TW202228779A (zh) * 2017-03-01 2022-08-01 英商梅迪繆思有限公司 抗rsv單株抗體配製物
WO2019152600A1 (en) * 2018-01-31 2019-08-08 The Wistar Institute Of Anatomy And Biology Nucleic acid antibody constructs for use against respiratory syncytial virus
CN111606993B (zh) * 2019-02-26 2022-06-28 中国科学院上海生命科学研究院 抗呼吸道合胞病毒的全人广谱中和抗体4f1及其应用
US12024553B2 (en) 2019-04-30 2024-07-02 Medimmune Limited Dosage regimens for and compositions including anti-RSV antibodies
EP4402166A2 (en) 2021-09-13 2024-07-24 MedImmune Limited Prevention of respiratory syncytial virus lower respiratory tract infection with nirsevimab
CN116987183B (zh) * 2022-07-22 2024-10-15 北京智仁美博生物科技有限公司 抗呼吸道合胞病毒中和性抗体及其用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
JP2008518936A (ja) * 2004-10-29 2008-06-05 メディミューン,インコーポレーテッド Rsv感染症および関連状態を予防および治療する方法
AU2005335714B2 (en) * 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
SG178712A1 (en) 2006-10-02 2012-03-29 Medarex Inc Human antibodies that bind cxcr4 and uses thereof
CN101679513A (zh) 2007-03-06 2010-03-24 西福根有限公司 用于治疗呼吸道合胞病毒感染的重组抗体
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
AU2008268362A1 (en) 2007-06-26 2008-12-31 Medimmune, Llc Methods of treating RSV infections and related conditions
US8092804B2 (en) * 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
EP2240581B1 (en) 2008-01-15 2016-05-11 AbbVie Inc. Improved mammalian expression vectors and uses thereof
ES2666584T3 (es) * 2009-07-15 2018-05-07 Aimm Therapeutics B.V. Medios y métodos para producir anticuerpos de alta afinidad
CA2776249C (en) 2009-10-06 2021-01-19 Medimmune Ltd Rsv-specific binding molecule
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
US20120263715A1 (en) 2009-10-28 2012-10-18 Medimmune, Llc Topical Methods Of Treating RSV Infections And Related Conditions
EP2825191B1 (en) 2012-03-16 2019-08-28 University Health Network Soluble toso protein and its use in treating autoimmune disorders
IN2014DN09951A (enExample) * 2012-05-22 2015-08-14 Shire Human Genetic Therapies
DK2950886T3 (da) 2013-02-01 2020-03-23 Medimmune Llc Respiratorisk syncytialvirus-f-protein-epitoper
SI3094353T1 (sl) 2014-01-15 2020-07-31 Medimmune, Llc RSY-specifična protitelesa in njihovi funkcionalni deli
EP3589318A1 (en) 2017-03-01 2020-01-08 MedImmune Limited Formulations of monoclonal antibodies
TW202228779A (zh) 2017-03-01 2022-08-01 英商梅迪繆思有限公司 抗rsv單株抗體配製物

Also Published As

Publication number Publication date
AU2020203831A1 (en) 2020-07-02
LT3094353T (lt) 2020-08-10
CN116355080A (zh) 2023-06-30
CN105916520A (zh) 2016-08-31
AU2021204339B2 (en) 2024-11-14
MX374517B (es) 2025-03-06
BR112016015044A2 (pt) 2017-09-19
US20190106482A1 (en) 2019-04-11
CA2933200C (en) 2025-05-06
JP6836398B2 (ja) 2021-03-03
WO2015108967A8 (en) 2015-10-01
LTPA2023514I1 (enExample) 2023-05-25
CA2933200A1 (en) 2015-07-23
WO2015108967A2 (en) 2015-07-23
LTC3094353I2 (enExample) 2025-07-10
US11186628B2 (en) 2021-11-30
US11661449B2 (en) 2023-05-30
TW201612191A (en) 2016-04-01
AU2025201056A1 (en) 2025-03-06
HUS2300019I1 (hu) 2023-05-28
US20230365660A1 (en) 2023-11-16
MX2016008639A (es) 2017-02-15
JP2023052693A (ja) 2023-04-11
CY1123425T1 (el) 2021-12-31
SI3094353T1 (sl) 2020-07-31
RS60387B1 (sr) 2020-07-31
HUE048855T2 (hu) 2020-08-28
NL301228I1 (enExample) 2023-05-03
ES2795727T3 (es) 2020-11-24
SMT202000282T1 (it) 2020-07-08
US20250179153A1 (en) 2025-06-05
AU2021204339A1 (en) 2021-07-22
US20200331989A1 (en) 2020-10-22
FR23C1016I1 (fr) 2023-06-23
US10689437B2 (en) 2020-06-23
FIC20230016I1 (fi) 2023-04-26
EP3094353B1 (en) 2020-04-01
PL3094353T3 (pl) 2020-09-07
RU2016133247A3 (enExample) 2019-01-16
EP3741390A1 (en) 2020-11-25
CY2023011I1 (el) 2023-11-15
EP3094353A4 (en) 2017-09-06
WO2015108967A3 (en) 2015-09-03
NL301228I2 (nl) 2023-09-13
EP4353316A2 (en) 2024-04-17
KR102188437B1 (ko) 2020-12-08
AU2015206570A1 (en) 2016-07-14
HRP20200607T1 (hr) 2020-07-10
CY2023011I2 (el) 2023-11-15
DK3094353T3 (da) 2020-06-02
PT3094353T (pt) 2020-06-08
TWI705974B (zh) 2020-10-01
JP2017504321A (ja) 2017-02-09
US20160340414A1 (en) 2016-11-24
RU2016133247A (ru) 2018-02-20
JP2025063143A (ja) 2025-04-15
HK1225992A1 (en) 2017-09-22
US20220098285A1 (en) 2022-03-31
BR112016015044A8 (pt) 2023-04-11
US12173050B2 (en) 2024-12-24
LUC00305I2 (enExample) 2025-09-22
EP3094353A2 (en) 2016-11-23
KR20160104018A (ko) 2016-09-02
EP4353316A3 (en) 2024-08-21
JP2020103293A (ja) 2020-07-09

Similar Documents

Publication Publication Date Title
DK3183051T3 (da) Væske-til-luftmembranenergivekslere
DK3134402T3 (da) 4-amino-imidazoquinolinforbindelser
DK3006072T3 (da) Karadgang
DK3211743T3 (da) Ø-til-netværk-omskiftningsfremgangsmåde
DK3222714T3 (da) Phytasemutanter
DK3119396T3 (da) Muscarinreceptoragonister
EP3230438C0 (en) N-GLYCOSYLATION
NL301228I2 (nl) nirsevimab
DK3183340T3 (da) Termolabile exonukleaser
EP4011484C0 (en) CARBONIC ANHYDRASE OF THERMOVIBRIO AMMONIFICANS
DE112015001664A5 (de) Betätigungsaktuator
DE112015005041A5 (de) Gargerätevorrichtung
DK3154703T3 (da) Fuldkappe-snekkecentrifuge
DK3110439T3 (da) Pcsk9-vacciner
DE102014000623A8 (de) Halbhohlnietelement
DK3009858T3 (da) Skyradar
DE112015001633A5 (de) Betätigungsaktuator
DK3447493T3 (da) Proteinrettede ortologer
ES1133830Y (es) Columbario
DE202014005655U8 (de) llluminationsvorrichtung
DE112015005055A5 (de) Gargerätevorrichtung
DK3091875T3 (da) Vipbar taburet
DK3191825T3 (da) Kreatininbiosensor
FI10894U1 (fi) Putkieristyskouru
ES1137381Y (es) Trompo